CONCEPCION MANGASEP: Open Payments
NPI 1861441701 · BUENA PARK, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,953 in 25 payments from 10 companies in 2025. Trend: 2023 $2,572 · 2024 $1,616 · 2025 $1,953
Food & beverage: $1,953
| Company | Payments | Amount |
|---|---|---|
| Alkermes, Inc. | 8 | $546 |
| Teva Pharmaceuticals USA, Inc. | 3 | $323 |
| Otsuka America Pharmaceutical, Inc. | 2 | $244 |
| Janssen Pharmaceuticals, Inc | 5 | $195 |
| E.R. Squibb & Sons, L.L.C. | 2 | $152 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 1 | $127 |
| Vanda Pharmaceuticals Inc. | 1 | $125 |
| Axsome Therapeutics, Inc. | 1 | $124 |
| Neurocrine BioSciences, Inc. | 1 | $96 |
| ABBVIE INC. | 1 | $21 |
Products named: LYBALVI, UZEDY, INVEGA SUSTENNA, ARISTADA, COBENFY, CAPLYTA, FANAPT, REXULTI.
Industry payments across CA — which companies pay providers there.
